Short description
Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.
Description
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Boston, Massachusetts, United States, North America
Founded on
October 1, 2018
Exited on
October 28, 2020
Went public on
October 28, 2020
Stock symbol
CERE
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$1230 - 4560
Sign in for full access
Investors
Blurry Noaccess, Noaccess, Nopepepe, Noaccess, Absolutely Noaccess, No Way, Nopepepe, Cannot Access, Blurry Noaccess, Noway Youcantaccess, Absolutely Noaccess, Noway Youcantaccess, No Way, Blurry Noaccess, Noway Youcantaccess, Noway Youcantaccess, Blurry Noaccess, Uh Ohhhh, Blurry Noaccess
Sign in for full access